Anticoagulation Reversal for Major Bleeding (ISTH 2025)
Anticoagulation Reversal for Major Bleeding (ISTH 2025): Major Bleeding on Anticoagulant → Identify Anticoagulant → Warfarin (VKA) → Supportive Care (Al...
Interactive Decision Tree
Algorithm Steps
- ▶Start
Major Bleeding on Anticoagulant
Life-threatening or critical site bleeding requiring reversal
- ◆Decision
Identify Anticoagulant
Which anticoagulant is the patient taking?
- ●Action
Warfarin (VKA)
Vitamin K antagonist reversal
- Check INR
- 4-Factor PCC 25-50 units/kg (based on INR)
- Vitamin K 10mg IV slow infusion
- Recheck INR in 30 min
- Target INR <1.5
- ●Action
Supportive Care (All Patients)
Standard hemorrhage management
- Hold anticoagulant
- IV access, type and screen
- Transfuse PRBCs for hemodynamic instability
- Consider platelets if plt <50k
- Local hemostatic measures
- Maintain normothermia
- ◆Decision
Bleeding Site
Location-specific considerations
- ⚠Warning
Intracranial Hemorrhage
Most urgent - rapid reversal critical
- Door-to-reversal time critical
- Target SBP <140 mmHg
- Neurosurgery consultation
- Repeat CT in 6 hours
- ICU admission
- ●Action
Reassess Response
Check hemostasis and labs
- Clinical bleeding assessment
- Repeat coagulation studies
- Consider re-dosing if ongoing bleeding
- Plan anticoagulation resumption timing
- ✓Outcome
Bleeding Controlled
Plan for anticoagulation resumption based on indication
- ●Action
GI Hemorrhage
Endoscopy when stable
- IV PPI (pantoprazole 80mg bolus)
- Gastroenterology consultation
- Endoscopy within 24h (or emergent if unstable)
- Transfuse to Hgb >7 (>8 if CAD)
- ●Action
Other Major Bleeding
Muscle, retroperitoneal, etc.
- Imaging to characterize
- Surgical/IR consultation as needed
- Embolization if appropriate
- Compartment syndrome monitoring
- ●Action
Dabigatran
Direct thrombin inhibitor reversal
- Idarucizumab 5g IV (2x2.5g vials)
- Full reversal within minutes
- Can re-dose if needed
- If unavailable: 4F-PCC 50 units/kg
- Hemodialysis removes ~60% in 2-3h
- ●Action
Factor Xa Inhibitors
Apixaban, rivaroxaban, edoxaban
- Andexanet alfa if available:
- Low dose: 400mg bolus + 4mg/min x2h
- High dose: 800mg bolus + 8mg/min x2h
- If unavailable: 4F-PCC 50 units/kg
- TXA 1g IV as adjunct
Guideline Source
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Specific reversal agents may not be available at all centers
- DOAC levels may not be immediately available
- Cost considerations may influence reversal agent choice
- Does not cover all anticoagulants (e.g., fondaparinux)
Applicable Regions
EU: Both specific reversal agents available
US: Andexanet alfa FDA-approved; idarucizumab available
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Absolute Neutrophil Count (ANC)
Absolute neutrophil count from CBC for neutropenia grading
Compare
AttendMe.ai vs OpenEvidence
See how this pathway workflow compares against OpenEvidence.
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Related Resources
Frequently Asked Questions
What is the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?
The Anticoagulation Reversal for Major Bleeding (ISTH 2025) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
What guideline is the Anticoagulation Reversal for Major Bleeding (ISTH 2025) based on?
This algorithm is based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH (DOI: 10.1016/j.jtha.2024.07.009).
What are the limitations of the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?
Known limitations include: Specific reversal agents may not be available at all centers; DOAC levels may not be immediately available; Cost considerations may influence reversal agent choice; Does not cover all anticoagulants (e.g., fondaparinux). Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Anticoagulation Reversal for Major Bleeding (ISTH 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free